PHYTOPROB’INOV

Contact : Florence CALDEFIE-CHEZET (Equipe ECREIN)

Background

GREENTECH (Saint-Beauzire) is a world leader in plant biotechnology, producing high-tech bioactive ingredients for the cosmetics, pharmaceutical, and nutraceutical sectors. The ECREIN academic research team at the Human Nutrition Unit (UCA - INRAE) is an expert in the study of immunocompetent cells, i.e., cells capable of generating an immune response.

Winners of the LabCom call for projects (a joint laboratory between a public research organization and a company), led by the French National Research Agency, Greentech and the academic research team are structuring their partnership and combining their skills and resources. Through this LabCom PHYTOPROB’INOV (PHYTO-PROBiotics, Obesity, Inflammation and inNOVation), with common governance and a common roadmap, a new generation of phyto-probiotics (combination of plant and bacterial ingredients) will be developed targeting adipocytes, i.e. the cells of adipose tissue (body fat mass) and the inflammation associated with excess weight.

Objective

The members of the PHYTOPROB'INOV LabCom are giving themselves five years to develop innovative products that can be used in the treatment of obesity and overweight associated with an inflammatory condition.

In addition to being part of the Clermont-Ferrand research promotion policy led by the University of Clermont Auvergne and INRAE, the PHYTOPROB'INOV LabCom is perfectly integrated into the I-Site CAP 20-25 project led by the UCA. Indeed, the scientific challenge "Personalized Mobility as a Key Factor in Health" aims to explore the various factors that influence the musculoskeletal system and propose optimization strategies. By targeting the impact of excess weight on individual mobility, the joint laboratory contributes to the challenge's research effort.

The Greentech company and the ECREIN Team of the Human Nutrition Unit (Université Clermont Auvergne - INRAE) are thus embarking on a joint adventure at the end of which new phyto-probiotics, for medical and cosmetic purposes, targeting obesity and overweight will be developed.

Impacts

Development of innovative "phyto-probiotics" targeting overweight/obesity and inflammation.